International Journal of Multidisciplinary Research and Growth Evaluation.

Organoids in Biotechnology: Biochemical Pathways Driving Personalized Medicine and Regenerative Therapies

Obinna CJ [1*], Godfrey EO [2], Emmanuel E [3], Abdusalam AO [4], Muhammad-Jamie A [5], Francis CO [6]
[1, 2] Department of Biochemistry, University of Benin City, 302001, Nigeria
[3] Department of Biochemistry, Delta State University, Abraka, Delta State, Nigeria, 340102
[4] Medicine and Surgery, Usman Danfodiyo University, Sokoto, Nigeria, 840104
[5] Medicine and Surgery, General Hospital, Bama, Borno State, Nigeria, 610213
[6] Biomedical Engineering, Afe Babalola University, Ekiti, Nigeria, 360102

* Corresponding Author: **Obinna CJ**

Article Info

ISSN (online): 2582-7138
Volume: 06
Issue: 04
July - August 2025
Received: 19-06-2025
Accepted: 22-07-2025
Published: 03-08-2025
Page No: 1103-1116

Abstract
Translational research has been transformed by organoid biotechnology, which offers physiologically realistic *in vitro* systems for regenerative medicine, tailored therapies, and disease modeling. The biochemical microenvironments that direct the creation of organoids are examined in this study, with a focus on the dynamics of the extracellular matrix and important signaling pathways like Wnt, Notch, BMP, and Hedgehog. As shown from previous research, one of the factors driving precision biomedicine is the combination of organoid systems and CRISPR-based gene editing. In addition to the review on advances made on vascularization, repeatability, and scale-up for clinical translation, we examine recent developments in organoid engineering, biobanking, and drug screening. The review finally highlights organoids as a crucial nexus between biochemistry and biotechnology, with growing uses in innovative healthcare.

DOI: https://doi.org/10.54660/.IJMRGE.2025.6.4.1103-1116

Keywords: Organoids, Biochemistry, Wnt/Notch/BMP Signaling, CRISPR, Personalized Medicine, Regenerative Biotechnology

1. Introduction

Organoids, which are three-dimensional, self-organizing multicellular constructs made from pluripotent or adult stem cells, have rapidly transformed into dynamic biochemical platforms that can replicate the molecular functionality and metabolic complexity of human organs [1, 2]. They provide patient-specific genetic environments, physiologically appropriate cellular microenvironments, and emergent metabolic zoning that are not conceivable with traditional systems given that they function as biochemical proxies of human tissues [1, 2].

Conventional 2D monolayer cultures have significant limitations, including the inability to maintain oxygen and food gradients, the absence of ECM-mediated cell-cell interactions, and altered gene expression and metabolic phenotypes that lead to misleading pharmacological responses [3, 4]. Meanwhile, animal models often show poor clinical predictivity due to interspecies variations in pharmacokinetics, signaling pathways, and metabolism [3, 5]. On the other hand, organoids made from patient samples preserve their natural genetic and epigenetic markers, allowing for more precise modeling of the pathophysiology of disease and the effectiveness of treatment [1, 6, 7].

Furthermore, a substantial correlation between clinical outcomes and organoid-based medication screening has been established. Functional drug sensitivity testing with organoids has a greater predictive accuracy than both 2D cell lines and patient-derived xenografts, according to meta-analyses [8, 9]. According to certain research, patients with metastatic colorectal cancer can have their chemoresistance and progression-free survival predicted by colorectal tumor organoids [10]. Organoids are strong biochemical and clinical models for precision oncology, according to these studies. There are three main goals for this review.

The first would be to examine critically, the molecular processes underlying metabolic dynamics, signaling route cross-talk, and organoid self-organization. By so doing, emphasize recent technical developments that improve the translational value of organoids, including co-culture systems, synthetic biochemical circuit integration, and CRISPR genome editing [11,8]. Then lastly, determine potential research areas where interdisciplinary convergence can propel the development of organoid platforms for regenerative therapies and precision medicine [12].

2. Organoids as Living Biochemical Systems: From Concept to Current Frontiers

2.1 Historical & Biological Foundations of Organoid Technology

Clevers and colleagues' 2009 announcement that a single Lgr5$^+$ intestinal stem cell could produce self-organizing, crypt-villus-like structures *in vitro* [13] marked a conceptual breakthrough in organoid science. This discovery questioned the widely held belief that complex cellular heterogeneity and spatial organization found in vivo could not be replicated *in vitro*. Organoid science has quickly developed from this basis into a multidisciplinary discipline that combines developmental biochemistry, translational biotechnology, and stem cell biology.

Prioritizing epithelial organoids, such as the gut, liver, and pancreatic systems, the early decade (2009–2015) gradually expanded into kidney structures, neurodevelopmental models, and airway organoids [14, 15]. Organoids are biochemical demonstrations of self-organized complexity: tissue-specific lineage commitment and spatial polarity are orchestrated by the activation of canonical pathways like Wnt, Notch, BMP, and Hedgehog [16, 17]. Early research showed that these pathways enabled stem cells to replicate niche-like conditions with the help of suitable extracellular matrices, such as Matrigel, maintaining both cell-intrinsic metabolic gradients and structural morphology [18].

Organoids maintain vertical stratification of biochemical signaling, replicating oxygen, nutrient, and cytokine gradients similar to those found in natural tissue [19], in contrast to monolayer cultures, which artificially flatten and homogenize cell activity.

A paradigm change emerged between 2015 and 2025 as organoid technologies were progressively included into translational pipelines. Organoids evolved from proof-of-concept developmental models to platforms for drug discovery, toxicological evaluation, regenerative therapy research, and patient-derived illness modeling [20, 21]. Particularly in oncology, where tumor-derived organoids, or "tumoroids," showed exceptional prognostic value for chemotherapeutic response [22], clinical programs began to incorporate organoid biobanks for adapting precision medicine techniques. During this time, biochemistry, materials science, and bioengineering converged to transform organoids from laboratory rarities into instruments with immediate practical applications [23].

The fundamental idea that tissue functionality is determined by biochemical surroundings rather than only genetic blueprints is emphasized in the foundations of organoid science. This knowledge sets organoids apart from other culture systems and explains why they are now regarded as the most effective way to replicate human biology *in vitro*. Organoids are positioned as essential models that bridge the gap between bench discovery and clinical implementation as research continues to improve their biochemical integrity.

2.2 Organoids as Biochemical Proxies vs. 2D and Animal Models

The ability of organoids to function as living biochemical proxies of human tissues constitutes what makes them distinctive; it provides an equilibrium between translationally defective animal models and overly basic 2D cell cultures. For many years, traditional 2D monolayer cultures have dominated *in vitro* research due in large part to their affordability, ease of application, and scalability. Their drawbacks are significant, though: cells cultured on flat, rigid surfaces lose important polarity, spatial orientation, and communication mediated by the extracellular matrix (ECM), which compromises their biochemical integrity [24].

In light of this, gene expression profiles differ significantly from those found in native tissues, and cells often take on stress-response phenotypes that change medication sensitivity and metabolism [25]. Organoids, on the other hand, maintain the three-dimensional microenvironment necessary for authentic biological reactions. Organoids' nutrient gradients, oxygen diffusion patterns, and paracrine signaling are similar to those found in vivo, promoting metabolic zonation, physiological gene expression, and differentiated cell identities that are challenging to replicate in flat monolayers [26].

In particular, brain organoids maintain glial–neuronal cross-talk essential for synaptic maturation, whereas liver organoids exhibit zonated metabolic activity across hepatocyte populations [27, 28]. These characteristics are essential for evaluating toxicological effects and pharmacokinetics in situations that are relevant to humans.

Despite their historical value, animal models have additional drawbacks. Translational results are often falsely positive or falsely negative because of interspecies differences in pharmacodynamics and molecular signaling [29]. For instance, medications that seem safe and effective in mice frequently don't work in human trials because of variations in immune responses and receptor architecture [30]. Nevertheless, whole-organ physiology is not entirely replicated by organoids. Among the limitations of this include the lack of stromal and immunological components necessary for thorough tissue mimicry [31] and the absence of vasculature, which limits organoid growth and oxygen transport.

But new developments like organoids-on-chips and multi-organoid assemblies are filling these gaps by combining heterotypic cell types with microfluidic perfusion to replenish lost biochemical components [32]. Therefore, organoids provide a quantum leap in biochemical fidelity, even though 2D cultures and animal models are still useful. They become essential instruments for translational biotechnology in the

future by fusing the human significance of clinical biology with the experimental accessibility of *in vitro* systems.



Fig 1: Schematic depiction of organoid derivation from pluripotent stem cells (PSCs). Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can generate the three germ layers—endoderm, mesoderm, and ectoderm—leading to organ-specific organoids [44].

2.3 Comparative Insights: Strengths and Limitations Relative to Animal Models and 2D Cultures

Translational research stays centered around the question of how effectively experimental models can replicate authentic human biochemistry. Despite their long-standing dominance, traditional 2D monolayer cultures and animal models are both limited in their ability to capture the biochemical complexity unique to humans. A third paradigm has arisen: organoids, which have special benefits but drawbacks of their own. Despite being vital for basic research and high-throughput tests, two-dimensional cultures naturally flatten cell shape, interfere with polarity, and remove crucial extracellular matrix (ECM) interactions [33]. These distortions reduce the predictive validity of pharmacological tests by causing abnormal gene expression and metabolic phenotypes [34]. By reestablishing three-dimensional cell-cell and cell-ECM connections, organoids get over these obstacles and allow for tissue-like spatial gradients of nutrients, oxygen, and signaling molecules [35]. Hepatocyte organoids, for instance, show metabolic zonation across lobule-like structures, a characteristic that monolayers cannot replicate [36].

2.3.1. Benefits Concerning Animal Models

Because they provide entire physiology with vascular, immunological, and endocrine components, animal systems are still highly effective for systemic research. However, interspecies heterogeneity frequently compromises their translational reliability. Drugs that perform well in preclinical studies but poorly in patients are often the result of differences in pharmacokinetics, receptor expression, and immunological pathways between humans and animals [37]. By maintaining human-specific genetic and epigenetic markers, organoids avoid these problems [38]. In comparison to xenografts, patient-derived tumor organoids (PDOs) have shown significantly higher predictive accuracy for chemotherapy responses [39].

2.3.2 Organoids' Drawbacks

Organoids have shortcomings despite their potential. Their absence of vascularization is a significant obstacle, limiting organoid size and impeding long-term viability because of inadequate oxygen and nutrient transport [40]. Moreover, their reliability for simulating intricate tissue-level biochemistry is diminished when stromal, immunological, and endothelial components are absent. Heterogeneity between replicates is another consequence of self-organization variability that makes reproducibility more difficult [41].

2.3.3 Innovations in Hybrids: Filling the Gap

Recent developments aim to use hybrid systems to lessen these disadvantages. Through the integration of microfluidics, organoids-on-chips allow perfusion to replicate gradient dynamics and vascular flow [42]. To replicate inter-tissue biochemical interactions, assembloids—fusions of various organoid types—incorporate heterotypic cell populations [43].

Table 1: Comparative strengths and limitations of organoids, 2D cultures, and animal models as biochemical systems

Model System	Key Strengths	Major Limitations	Translational Relevance
2D Monolayer Cultures	Easy to establish; cost-effective; high-throughput compatible	Loss of polarity; disrupted ECM interactions; aberrant gene expression; poor metabolic fidelity	Low — limited predictive value for drug response
Animal Models	Whole-organism physiology; vascular, immune, and endocrine systems intact	Interspecies variation; ethical issues; high cost; poor predictive translation in many cases	Moderate — useful for systemic studies but limited in human-specific insights
Organoids	Human-derived; preserve 3D architecture, gradients, and heterogeneity; patient-specific	Lack vasculature; absence of stroma/immune cells; heterogeneity in self-organization; size	High — strong predictive accuracy; bridges gap between 2D and animal

	PDOs for precision medicine	limitations	models

3. Biochemical Signaling Pathways Underpinning Organoid Development

3.1 Canonical Pathways and Their Interactions

Fundamentally, stemness, lineage commitment, and spatial organization are determined by canonical biochemical reactions that orchestrate organoid systems. In organoid cultures, stem cell self-renewal continues to be dependent on the Wnt signaling pathway. It regulates the transcription of target genes necessary for maintaining stemness, nuclear translocation, and β-catenin stabilization [44]. Exogenous Wnt ligands or R-spondins are necessary in intestinal and gastric organoids to avoid premature differentiation, highlighting the critical function of Wnt in epithelial regeneration [45]. Loss of organoid integrity results from stem cells' normal death or differentiation into other cell types when Wnt activity is absent [46].

The Notch pathway works synergistically with Wnt to regulate the balance between stemness and differentiation. Notch activation via ligand-receptor interactions (e.g., Delta-like ligands binding Notch1) suppresses secretory lineage differentiation [47] and stimulates the maintenance of progenitor pools. For instance, Notch activation suppresses Atoh1 expression in intestinal organoids, which prevents goblet cell specification [48]. Its function in maintaining proliferative compartments is highlighted by the observation that crypt maintenance requires constant Notch signaling.

Wnt and Notch are opposed by the Bone Morphogenetic Protein (BMP) pathway in a variety of instances, which is equally important. BMP ligands constrain the stem cell zone [49] and induce epithelial progenitors to differentiate. In cerebral organoids, BMP signaling has been shown to enhance glial lineage specification, while its restriction favors neuroepithelial stem cell expansion [50]. Therefore, appropriate zonation within organoids is made possible by the dynamic interaction between BMP and Wnt, which replicates tissue gradients in vivo.

Additional layers of control are introduced by other canonical pathways. Hedgehog signaling controls polarity and morphogen gradients in organoids and is essential for anterior-posterior axis patterning in embryogenesis. Research in neuronal and pancreatic organoids shows that Hedgehog activity stimulates spatial compartmentalization and branching morphogenesis [51].

The Hippo pathway regulates organoid size and growth through two main effectors, YAP/TAZ. While YAP inhibition causes apoptosis and lowers structural complexity, hyperactivation of YAP results in hyperproliferation and dysplastic structures [52].

Crucially, organoid morphogenesis depends on the integration of these networks through feedback loops. For instance, Wnt and Notch typically act together to maintain stemness, while BMP provides counter-regulatory input to ensure differentiation happens in the right domains [53]. Similarly, Hippo pathway modulation feeds back into Wnt activity by modifying β-catenin's nuclear availability [54]. Because redundancy maintains structural integrity even in the presence of disruption, this cross-talk highlights the metabolic robustness of organoid systems. Together, these canonical pathways offer the molecular basis for the complexity of organoid models.



Fig 2: Canonical Wnt signaling pathway showing inactive and active states. Key molecular players include APC, GSK3β, and TCF/LEF transcription factors. This pathway is central in regulating stemness and differentiation during organoid morphogenesis [65]

3.2 Epigenetic and Epitranscriptomic Modulators

Organoid lineage commitment and stability relies significantly on epigenetic control in addition to conventional signaling. The accessibility of genes linked to stemness is influenced by DNA methylation patterns. In intestinal organoids, for instance, increased stem cell competency is correlated with demethylation at the Lgr5 promoter [55]. Conversely, chemoresistance phenotypes have been linked to

aberrant hypermethylation of tumor suppressor genes inside tumor-derived organoids, indicating clinically significant epigenomic reprogramming [56].

Transitions between pluripotency and lineage specification are regulated by histone modifications, such as H3K27me3 and H3K4me3 marks. For example, temporal waves of histone acetylation in cerebral organoids correlate to neurogenic versus gliogenic phases [57]. In addition to regulating differentiation trajectories, these changes also stabilize transcriptional outputs, preventing random drifts that might compromise duplicate repeatability. Histone landscapes can currently be precisely mapped using emerging approaches like CUT&Tag and ChIP-seq in organoids, which provide previously unattainable chromatin state resolution [58].

The function of chromatin remodeling complexes, such SWI/SNF, in adjusting the accessibility of lineage-specific loci is equally revolutionary. It has been demonstrated that mutations in SWI/SNF subunits inside tumor organoids alter biochemical reactivity, resulting in specific susceptibilities to epigenetic inhibitors [59]. This interaction demonstrates how chromatin states and biochemical signals work together to calibrate organoid phenotypes.



Fig 3: Overview schematic of Hedgehog, Notch, and TGF-β pathways. These signaling cascades integrate to control polarity, growth, and lineage commitment in organoids. Key regulators include Sonic Hedgehog (SHH), Notch intracellular domain (NICD), and Smad complexes [65].

Epitranscriptomic control, specifically N6-methyladenosine (m6A) alterations, has been identified as a fine-tuner of organoid growth at the RNA level. m6A methylation of transcripts encoding differentiation regulators speeds up mRNA degradation in intestinal and hepatic organoids, maintaining stem cell pools [60]. The disruption of m6A writers (METTL3/METTL14) or erasers (FTO/ALKBH5) results in impaired organoid viability and flawed lineage trajectories [61]. Significantly, distinct m6A landscapes between organoids produced from healthy tissue and tumors have been found, offering a molecular basis for the observed variation in drug responses [62].

Lastly, new data indicates that in organoid systems, epigenomic plasticity supports both heterogeneity and stability. Reproducibility is guaranteed by stable chromatin landscapes, while low-level plasticity might enable organoids to dynamically adjust to metabolic disturbances and culture stresses [63]. However, variability is introduced by this plasticity, which presents an interesting challenge for translational applications. Continuous attempts to standardize epigenomic states, including chemical modulators and CRISPR-based epigenome editors, have the potential to increase uniformity without compromising adaptability [64].

4. Engineering Organoid Systems through Biochemical and Genetic Interventions

Organoid technology has advanced into an era of active engineering, no longer limited to passive mimicking of tissue development. The application of synthetic biochemical circuits and precise genome editing, which transform organoids from descriptive systems into programmable platforms for translational biotechnology, is essential to this advancement. These modifications open up whole new possibilities for disease modeling and therapeutic testing, improve repeatability, and deepen functional relevance.

4.1 CRISPR and Precision Genome Editing in Organoid Biotechnology

Functional Genomics in Patient-Derived Organoids

The prospect of patient-derived organoids to serve as precision genomic laboratories has been completely transformed by the emergence of CRISPR-Cas9 and its derivatives. Researchers may determine causative pathways in a natural cellular establishing by introducing certain

changes in genes linked to disease. For example, researchers may map biochemical changes from early dysplasia to invasive carcinoma [66] by using colorectal cancer organoids altered at the APC or KRAS loci to replicate tumor growth trajectories with previously unobtainable fidelity. Direct biochemical readouts of therapy effectiveness are also provided by cystic fibrosis organoids produced from CRISPR-corrected CFTR mutations, which exhibit restored chloride ion channel activity [67].

In this context, functional genomics aids drug-gene interaction investigations, including the discovery of synthetic lethalities and drug resistance mechanisms, and extends beyond disease modeling. For instance, precision pharmacology has been informed by the use of targeted editing of cytochrome P450 isoforms in hepatocyte organoids to elucidate inter-individual heterogeneity in xenobiotic metabolism [68].

CRISPR-Driven Disease Modeling: Oncology, Neurology, and Rare Genetic Disorders

Iterative modeling of tumor heterogeneity made possible by CRISPR-enabled organoids has revolutionized oncological research. Multiplex CRISPR screening of tumor-derived organoids (PDOs) has identified driver mutations that determine responsiveness to checkpoint inhibitors and trigger tumorigenesis [69].

Rett syndrome characteristics have been replicated in brain organoids with CRISPR-induced MECP2 mutations in neurology, offering a useful platform for evaluating epigenetic medications [70]. Similarly, by identifying modulatory nodes for neuroprotective intervention, CRISPR alteration of α-synuclein in midbrain organoids has made it possible to recreate dopaminergic neuron loss pathways in Parkinson's disease [71].

Additionally, rare genetic illnesses that used to be limited by the lack of compatible models are becoming more manageable. For diseases such as Fanconi anemia, where hematopoietic progenitor organoids demonstrated restored DNA repair capacity after editing, CRISPR-corrected organoids have demonstrated therapeutic potential [72].

Case Studies of Translational Progress (2020–2025)

A series of translational discoveries between 2020 and 2025 validated the medical significance of CRISPR-organoid integration. Glioblastoma patient organoids were utilized to model gene therapy approaches that target EGFRvIII, which decreased tumorigenic signaling cascades *in vitro* and was associated with better results in patient-matched xenografts [73]. CRISPR editing of HNF1B has been employed in hepatobiliary organoids to discover metabolic vulnerabilities and elucidate the mechanisms of cholangiocarcinoma initiation [74].

CRISPR-modified intestinal organoids have advanced into preclinical pathways for ex vivo cell replacement treatments, which is equally appealing. Researchers demonstrated therapeutic scalability in preclinical conditions by restoring the function of epithelial ion channels by repairing CFTR mutations [75]. These case studies demonstrate how CRISPR allows organoids to prospectively shape treatment interventions in addition to reflecting human illness.

4.2 Synthetic Biochemical Circuits in Organoid Engineering

4.2.1 Introduction of Synthetic Feedback Loops for Controlled Biochemical Outputs

Synthetic biology, where biochemical circuits are created to dynamically regulate cell behavior, is the next frontier in organoid engineering. In order to control metabolic fluxes and preserve stable tissue architecture, artificial feedback loops have been added to intestinal and hepatic organoids. For example, crypt-villus polarity has been demonstrated to be maintained under long-term culture conditions by optogenetically controlled synthetic promoters controlling Wnt ligand expression [76]. Reproducibility is directly improved by these constructed feedback mechanisms, which lessen the drift and variability typical of protracted organoid cultures.

4.2.2 Biochemical Rewiring for Enhanced Reproducibility and Drug-Testing Fidelity

In organoid research, drug-testing fidelity is still a major obstacle. Pharmacodynamic readouts are frequently distorted by variations in metabolic zonation and lineage makeup. This problem can be solved by rewiring intracellular decision-making processes using synthetic biochemical circuits. For instance, synchronized differentiation of epithelial progenitors has been made possible by inducible constructs that target the Notch signaling cascade, standardizing the cell populations employed in pharmacological experiments [77]. Similarly, to improve assay reliability in chemotherapeutic screens, stochastic clonal proliferation has been inhibited by biochemically rewiring the PI3K/AKT pathways in tumor organoids [78].

4.2.3 Integration with Optogenetics and Inducible Biochemical Systems

Programmable living platforms are the result of the combination of optogenetics, inducible biochemical systems, and organoid biotechnology. The precise spatiotemporal regulation of neuronal lineage development in neural organoids has been made possible by light-inducible systems that regulate Hedgehog pathway activity, providing mechanistic insights into cortical layering [79]. Doxycycline-inducible transcriptional switches that control Hippo signaling have been employed in hepatic organoids to regulate hepatocyte proliferation without leading to abnormal growth [80].

In addition to increasing experimental control, these integrations make closed-loop therapy testing possible, allowing organoid biochemical states to be dynamically modified to replicate patient-specific circumstances. Going forward, organoids are positioned as programmable bio-computational devices that can decode and react to complex biochemical landscapes in both clinical and research applications owing to the combination of synthetic circuit design and CRISPR-based precision editing [81].

5. Integration of Genetic and Epigenetic Engineering

5.1 CRISPR/Cas Systems in Organoids

The functional range of organoid systems has been significantly impacted by the development of CRISPR/Cas technology. CRISPR allows for high-fidelity gene editing, which may accurately duplicate patient-specific mutations, excise defective alleles, or add therapeutic modifications, in contrast to previous mutagenesis techniques. In light of this capacity, patient-derived organoids (PDOs) are essential for analyzing disease causes and identifying specific therapies. For instance, intestinal organoids from patients with cystic fibrosis that were altered using CRISPR/Cas9 showed that CFTR channel function was restored, confirming the system's

potential for therapeutic use in practical settings [82]. To replicate tumor suppressor loss, oncogene activation, and drug resistance pathways with unmatched fidelity, similar techniques have been used in cancer organoids [83, 84].

Organoids are now platforms for extensive gene-function mapping, going beyond their use as models as a result of functional genomics leveraging CRISPR screens. For example, synthetic fatal vulnerabilities that can be tackled by oncology have been identified through genome-wide CRISPR alterations in pancreatic and liver organoids [85]. Furthermore, researchers can modify transcriptional outputs without causing double-strand breaks by combining the CRISPR interference (CRISPRi) and activation (CRISPRa) systems, which enables reversible functional studies [86]. By using these methods, organoid research is guaranteed to both replicate sick conditions and identify the causal molecular networks that underlie disease phenotypes.

The use of CRISPR in organoids is not without challenges, despite its potential. In many organoid systems, homology-directed repair (HDR) is still not very effective, especially when it pertains to non-dividing cells [87]. Additionally, there are risks associated with off-target editing and mosaicism that can complicate experimental conclusions. Novel Cas variations like Cas12 and Cas13, together with base editing and prime editing systems, are being included into organoid research to overcome these constraints [88]. All things taken into account, CRISPR-driven engineering in organoids is a frontier where translational biotechnology and functional genomics meet to provide accurate insights into human pathophysiology [89].

5.2 Epigenetic Reprogramming

Organoids' biochemical identities are not exclusively determined by their genetic makeup; rather, phenotypic plasticity, cellular heterogeneity, and lineage commitment are all significantly influenced by epigenetic control.The way stem cells in organoids read developmental stimuli is coordinated by DNA methylation patterns, histone modifications, and RNA epitranscriptomic markers like m6A.

For example, research on cerebral organoids has shown that, similar to in vivo neurodevelopment, dynamic DNA methylation controls the development of neuroepithelial progenitors into cortical neurons [90]. Enhancer activity in hepatic organoids is regulated by histone modifications, specifically H3K27me3 and H3K4me3, which maintain the equilibrium between differentiation and proliferation [91]. Additionally, it has been demonstrated that abnormal epigenetic states in tumor organoids produced from patients sustain characteristics of cancer, such as metabolic rewiring and stemness [92].

An additional axis of regulation is provided by RNA epigenetics. Modifications to m6A influence the translation of mediators of the Wnt and Notch pathways, which fine-tunes organoid morphogenesis [93]. In gut organoids, the depletion of m6A regulators such METTL3 or FTO has been connected to disturbed epithelial polarity and poor stem cell renewal [94]. Crucially, small-molecule inhibitors of DNA methyltransferases and histone deacetylases are being used more and more to evaluate epigenetic interventions in organoids, allowing for reversible reprogramming of organoid states [95]. These methods model both genetic and epigenetic factors of disease, expanding the translational utility of organoids.

5.3 Synthetic Biology Approaches

Given that synthetic biology enables programmed control over biological and biochemical functions, it provides a compelling extension of organoid engineering. Synthetic feedback circuits can be used to give organoids regulated outputs like drug sensitivity, stress resistance, or inducible differentiation [96]. For instance, optogenetic-driven synthetic transcriptional switches have been used in cerebral organoids to control neural network activity in real time [97].

Biochemical rewiring to improve organoid repeatability is another frontier. Scalability for clinical applications is frequently limited by the intrinsic variability introduced by self-organizing systems. To reduce inter-organoid variability, synthetic circuits that standardize Wnt and Notch signaling thresholds are being constructed [98]. Similar to this, inducible gene circuits in conjunction with microfluidic organoid-on-chip devices allow for the spatiotemporal regulation of vascular mimicry, overcoming the constraints of oxygen diffusion and nutrition delivery [99]. Furthermore, the combination of organoid biotechnology and synthetic biology creates opportunities for precision medicine. As pre-clinical models for "smart" anti-cancer treatments, custom circuits that may identify oncogenic biomarkers and cause apoptosis in tumor organoids have been proposed. Organoids can be transformed from passive models into active testbeds for novel treatment approaches by combining computational modeling, inducible promoters, and feedback regulators.

6. Regenerative Medicine: Biochemical Challenges and Innovations

Organoids have recently been in the clinical spotlight after emerging from the realm of developmental biology as viable options for regenerative treatments. However, significant biochemical obstacles still stand in the way of turning organoids into practical transplant alternatives. Vascularization, immunological integration, and reaching functional maturity on par with native tissues are the most important of these. This section explores these frontiers, emphasizing the ways in which biochemical advancements are progressively closing the gap between clinical transplantation and lab-grown organoids.

6.1 Vascularization and Perfusion at the Biochemical Level

The lack of functional circulatory networks is one of the major obstacles in organoid transplantation [100] Tissues in vivo depend on complex capillary beds for waste elimination, oxygen exchange, and nutrition supply. However, organoids usually depend on passive diffusion, which significantly restricts their functioning and SIZE [101]. As organoids grow over 200–300 µm without vascularization, necrotic cores form, making them unfit for therapeutic use [102].

Biochemical engineering techniques aim to address this by modifying the extracellular matrix (ECM) and adding growth factors to promote angiogenesis. The most extensively researched pro-angiogenic agent is vascular endothelial growth factor (VEGF), which has been shown to strongly stimulate the ingrowth of endothelial cells into cerebral and hepatic organoids [103].

By mobilizing pericytes and smooth muscle cells, the combination of fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), and angiopoietins has further enhanced vascular stability [104].

Self-assembled microvasculatures within kidney and liver organoids have been made possible by recent developments in biofabrication, which have enabled the embedding of endothelial progenitor cells into hydrogel scaffolds enhanced with biochemical cues [105]. Furthermore, organoids are being preconditioned under low oxygen circumstances by hypoxia-inducible factors (HIFs), which promote angiogenic signaling prior to transplantation [106]. Perfusable, hierarchical vascular network orchestration is still a challenge, highlighting the necessity of integrative biochemical and biomechanical approaches.

6.2 Immune–Organoid Interfaces

Another major challenge is immunological rejection, even in the event that vascularization is accomplished. Through biochemical recognition pathways, the immune system recognizes foreign organoid grafts, frequently leading to cytotoxicity, inflammation, and ultimately graft loss [107]. For transplantation to be successful, it is now essential to understand and modify the immune–organoid contact.

Cytokines, chemokines, and cell surface molecules such MHC class I and II complexes facilitate crosstalk between organoid cells and host immune cells [108]. Among the pharmacological strategies to promote tolerance is the modification of checkpoint pathways (e.g., PD-1/PD-L1) that inhibit T-cell activation [109]. Additionally, concealing organoids from natural killer (NK) cell monitoring has shown potential when non-polymorphic HLA-E or HLA-G are introduced in conjunction with CRISPR-based ablation of immunogenic HLA molecules [110].

In addition to genetic editing, soluble substances like TGF-β and IL-10 have been introduced into organoid cultures to create an anti-inflammatory milieu [111]. Furthermore, in preclinical liver and kidney organoid transplantation models, co-culture systems involving regulatory T cells or mesenchymal stem cells have shown immune-modulatory effects, minimizing graft rejection rates [112]. However, ensuring that organoids can flexibly adjust to inflammatory triggers without losing function is also necessary for long-term immunological integration. In order to provide a "smart cloaking" strategy, strategies increasingly center on artificial circuits that enable organoids to release immunomodulatory chemicals in response to cytokine surges [113].

6.3 A Future toward Functional Transplants

Liver, kidney, and intestinal organoids are at the forefront of the biochemical milestones that are being steadily reached in the direction of functional transplantation. The capacity to integrate into mouse models has been shown by liver organoids, which can secrete albumin and metabolize xenobiotics at physiologically appropriate quantities [114]. Their long-term survival is still dependent on hepatocyte and bile canaliculi reaching full maturation, which is controlled by the Wnt/β-catenin and HGF signaling pathways [115]. Nephron-like structures, including as podocytes and proximal tubules, that are able to filter and partially reabsorb substances have been effectively generated by kidney organoids [116]. However, functional equivalency to native kidneys is still limited by biochemical constraints in fluidic perfusion and glomerular basement membrane assembly [117]. Another intriguing option is intestinal organoids, which have been transplanted into pig and mouse models, where they reestablished absorptive activity and assimilated into the mucosal lining [118]. VEGF-driven angiogenesis and Notch-mediated epithelial differentiation are critical for successful grafts [119].

In the future, biochemical coordination along three axes—vascularization for nutrition delivery, immune cloaking for tolerance, and inductive signaling for functional maturation—will be necessary to translate organoids into clinical medicines. Organoid transplantation may soon be a viable solution to the lack of donor organs due to the convergence of these biological milestones.

7. Organoid-on-Chip Technologies and Multi-Organoid Assemblies

The development of multi-organoid assemblies and organoid-on-chip devices represents a revolutionary advance in tissue engineering. Although conventional three-dimensional (3D) organoids already replicate the shape of original tissue, their physiological significance is increased to nearly in vivo fidelity by combining different types of organoids or integrating them with microfluidic platforms [120]. Major organoid research difficulties such as uneven nutrition distribution, lack of vascularization, and lack of inter-organ communication are tackled by these methods.

7.1 Microfluidics for Biochemical Precision

A level of biochemical precision that is not possible in static culture is made possible by organoid-on-chip systems, which use microfluidic engineering to provide regulated nutrition, oxygen, and signaling gradients [121]. By simulating vascular-like perfusion, microfluidics help to prevent hypoxia and necrosis, which frequently shorten the lifespan of traditional organoids [122]. Organoid-on-chip solutions support larger and more metabolically active structures by continually delivering medium and eliminating waste.

The integration of oxygenation channels and microvascular networks, which support organoids like the liver, kidney, and heart for prolonged culture periods, has been a significant advancement [123]. Additionally, these systems enable precise spatiotemporal manipulation of growth factors, which is essential for researching developmental pathways with higher repeatability, like Wnt, Notch, and Hedgehog [124]. Biosensor integration offers a potent real-time monitoring feature. Continuous readouts of the metabolic condition of the organoid are provided by embedded pH, oxygen, and metabolite sensors [125]. Organoid physiology may be dynamically assessed under drug exposure or immunological challenges because of the ability of electrochemical biosensors to track released cytokines, hormones, and metabolites [126].

Importantly, toxicology and pharmacology are adopting organoid-on-chip models. For instance, liver-on-chip models can predict hepatotoxicity with a precision that exceeds animal studies [128] and cardiac organoid chips with impedance sensors have been used to detect arrhythmic reactions to drug candidates [127]. By bridging the gap between *in vitro* biology and clinical translation, these developments collectively are establishing microfluidics as a fundamental component of organoid biotechnology.

8.0 Technical Barriers, Ethical Considerations, and Reproducibility Challenges

Organoid biotechnology's rapid progress has resulted in both significant obstacles and incredible promise. The field is at a turning point, with issues ranging from biochemical heterogeneity that affects reproducibility to moral quandaries

involving brain organoids and consciousness. Furthermore, as organoids approach clinical use, concerns regarding regulatory supervision and industrial scalability underscore the necessity of unified standards [129].

8.1. Biochemical Heterogeneity and Its Implications for Reproducibility

Biochemical variability, both within and between cultures, is one of the most enduring challenges in organoid research. Organoids exhibit variety in size, cellular composition, and differentiation state due to their self-organizing nature [130]. Divergent lineage paths can result from even minor variations in the composition of the extracellular matrix (ECM) or oxygen gradients [131]. This variation lowers the predictive value of organoid-based drug detection and makes comparative studies more difficult.

There is growing evidence that heterogeneity is further exacerbated by epigenetic drift across extended culture. Modifications in histone modification patterns and DNA methylation landscapes impact biochemical responsiveness and cell fate commitment [132]. Reproducibility may be compromised if two organoids made from the same patient sample are not closely monitored since they could develop into biochemically different entities. Intra-organoid diversity is now being measured using single-cell RNA sequencing and high-content imaging [133]. Standardizing results, however, is still challenging unless the biochemical microenvironment, which includes signaling factor concentrations, ECM stiffness, and nutrient transport, can be properly controlled [134].

8.2 Standardization of Biochemical Inputs

Standardizing the biochemical inputs that control organoid development is essential for reproducibility. Presently Matrigel, an ECM replacement produced from mouse sarcoma, is used in the majority of organoids. Experimental noise is introduced by the undefined and batch-variable protein composition of matrigel [135]. An option that offers precise control over integrin binding locations, stiffness, and growth factor retention is synthetic hydrogels built with programmable biochemical motifs [136].

Supplementing with growth factors is another cause of variability. The bioactivity of commercially available Wnt3a, R-spondin, and noggin varies often amongst suppliers [137]. Organoid morphology and signaling dynamics can be reshaped by inconsistent ligand activity, which can also change pathway activation thresholds. To combat this, a number of organizations support the development of chemically defined media that contain recombinant elements, hence removing variability originating from animals [138]. Protocols for a consensus culture are also being developed. Harmonized recipes for intestine, brain, and liver organoids are being tested by international consortia, including the Human Organoid Biobank Initiative [139]. To reduce stochastic variance, these procedures prioritize perfusion-based systems, specified ECMs, and uniform component concentrations.

8.3 Ethical Debates around Brain Organoids

The ethical issues raised by brain organoids rank among the most significant obstacles. Concerns over brain organoids' ability to mimic elements of human cognition have emerged as a result of their growing biochemical complexity, which includes spontaneous electrical activity, glial-neuronal cross-talk, and even synchronized oscillations [140].

The main point of contention is whether these biological indicators could be indicative of primitive sensibility or consciousness. Although there is currently evidence that brain organoids lack the architecture required for higher cognition [141] their electrical characteristics raise challenging moral considerations. Ethicists and philosophers support frameworks that strike a balance between protections against exploitation and scientific advancement [142].

Implementing ethical ceilings, which set limits on the developmental stages or network complexity organoids may reach *in vitro*, is one suggested strategy [143]. Others suggest continuous biochemical monitoring of activity thresholds (for example, by MEA recordings or calcium imaging) to make sure organoids don't exceed recognized ethical standards [144]. Potential applications in neuropsychiatric disease modeling, where optimizing biochemical authenticity may unavoidably push organoids toward morally dubious states, further complicate these discussions [145]. As a result, regulatory frameworks must advance with technology to maintain public confidence and support groundbreaking research.

8.4 Industrial Scalability, Regulatory Landscapes and Challenges

Industrial scalability is essential for organoids to transition from laboratory experiments to clinical treatments. The labor-intensive and low-throughput production technologies used now are not suitable for extensive translational use [146]. Pilot programs are currently underway for automated bioreactors intended for regulated growth factor supply, nutrition perfusion, and oxygenation [147]. By incorporating robotic handling, these systems allow for the concurrent manufacture of hundreds of organoids while lowering variability. Scalability necessitates long-term stability from a biological perspective. For lengthy periods of culture, organoids must maintain metabolic function, epigenetic integrity, and lineage fidelity [148]. Microfluidic oxygenation in conjunction with bioreactor-based methods shows potential in maintaining organoids at clinical grade [149].

Guidelines for organoid-based therapeutics are currently being drafted by regulatory bodies including the FDA and EMA, with an emphasis on quality control of biochemical characteristics such genetic stability, growth factor purity, and ECM composition [150]. Developing potency tests that accurately forecast in vivo activity is a significant issue. Commercialization on a broad scale could stagnate in the absence of proven benchmarks. Regulatory decision-making is also influenced by technological and ethical ambiguities. While commercialization approaches are complicated by intellectual property challenges surrounding CRISPR-modified organoids, the usage of animal-derived components (such as Matrigel) raises concerns over safety and reproducibility [151].

In the end, obtaining regulatory approval will necessitate not only technological advancement but also frameworks driven by consensus that balance scalable manufacturing, ethical protections, and biochemical rigor [152].

9. Future Directions and Prospects

Organoid biotechnology has undergone an incredible amount of development, yet its most revolutionary uses are still to come. Organoids have the potential to become predictive biochemical systems that revolutionize next-generation healthcare as a result of the convergence of artificial intelligence, customized medicine, and interdisciplinary

collaboration [153]. With an emphasis on personalized organoid biobanks, multidisciplinary integration, predictive modeling, and the future of organoids in medicine, this section examines the development of the area.

9.1 Combining AI-Powered Predictive Models to Optimize Biochemical Pathways

One important factor propelling organoid advancement is artificial intelligence (AI). Iterative testing is used in traditional organoid culture methods to identify the best growing and differentiating conditions. In contrast, real-time biochemical route optimization is made possible by AI-driven predictive models, which minimize trial-and-error [154]. Multi-omic datasets from organoid cultures, including transcriptomics, epigenomics, proteomics, and metabolomics, are being subjected to deep learning algorithms. These models can forecast the effects of oxygen gradients, ECM stiffness, and changing growth inputs on lineage specification [155]. For instance, to optimize fidelity to human developmental trajectories, reinforcement learning algorithms can iteratively modify Wnt, Notch, and BMP signaling inputs [156].

AI-enhanced organoids are being employed in drug research to model the biochemical reactions to therapeutic interventions. Predicting tumor organoid susceptibility to targeted medicines holds special promise in oncology, where it could transform individualized treatment plans [157]. Additionally, combining AI with high-throughput imaging reduces observer bias and standardizes analyses by providing automated readouts of organoid morphology and function [158] [159].

In the future, digital twins—virtual organoids that mimic genetic and metabolic alterations under various interventions—may be incorporated. Both basic research and clinical translation could be significantly accelerated by such twins.

9.2 Creating Customized Organoid Biobanks for Tailored Medical Care

One of the most interesting medical frontiers is the creation of customized organoid biobanks. A live repository of a person's tissues, patient-derived organoids (PDOs) capture both genetic and epigenetic contexts [160]. Clinicians can model rare diseases, conduct ex vivo drug screening, and forecast treatment outcomes without putting patients at risk by keeping these biobanks up to date [161]. Building population-scale organoid archives is a major endeavor, especially for infectious diseases, tumors, and neurodegenerative diseases [162]. In addition to enabling individualized care, these biobanks present unmatched chances to investigate biochemical variation among people, which may lead to the discovery of new biomarkers and treatment targets [163].

The harmonization of biobank methods is a significant obstacle. To guarantee that organoids maintain biochemical integrity after thawing, growth media compositions, cryopreservation techniques, and extracellular matrix scaffolds must be coordinated [164]. By anticipating which cryoprotectant combinations best preserve metabolic pathways, artificial intelligence (AI) techniques might be beneficial here [165]. Crucially, privacy and ethical issues are major concerns. Governance frameworks need to address consent, ownership, and data exchange because organoids are living tissues that have been obtained from patients [166].

9.3. The Role of Interdisciplinary Convergence in Advancing Organoid Biotechnology

It will be interdisciplinary convergence that will drive the next generation of organoid innovation. To deal with issues too complex for any one area, biochemistry, genetics, material science, bioengineering, computer science, and ethics must collaborate [167].

For example, microfluidics combine engineering control with biochemical accuracy to produce organoid-on-chip platforms that replicate physiological conditions [168]. By creating unique feedback loops and inducible biochemical systems, synthetic biology improves control and reproducibility [169]. In the meantime, AI and computational biology offer predictive models that turn unprocessed data into useful insights [170]. To guarantee that innovations are in line with social values, cooperation with ethicists and regulatory specialists is crucial, even beyond technical convergence [171]. In the absence of these frameworks, the public's trust may be weakened by the dangers of exploitation, unequal access, or premature translation.

These multidisciplinary efforts are already yielding positive results. Initiatives that connect liver, brain, and gut organoids have provided a sneak peek of multi-organ prediction systems and unveiled new insights about systemic biochemical communication [172]. The rate at which these advancements are occurring indicates that group collaboration, rather than solitary advancement, will determine the future of organoid biotechnology.

9.4. Prospects for Next-Generation Medicine: Organoids as Predictive Biochemical Systems

Organoids have the potential to develop from experimental models into biochemical systems that can be predicted in the future. They may soon function as ex vivo avatars of patient biology with the help of transdisciplinary infrastructure, standardized biobanking, and AI-guided optimization [173]. Before delivering medicines in vivo, these avatars would allow physicians to predict responses to treatments, model disease trajectories, and create precision interventions [174]. Organoids may soon advance from proof-of-concept grafts to functional transplants in regenerative medicine that are immunocompatible and have stable vascularization [175]. When combined with AI-powered feedback and ongoing observation, these transplants may be able to biochemically adapt to shifting physiological needs.

The complexity of the organoids themselves, as well as the surrounding technological and ethical environment, will determine the direction of organoid biotechnology in the future. Organoids could become the foundation of next-generation healthcare as innovation picks up speed, bridging the gap between bench and bedside in previously inconceivable ways [176].

10. Conclusion

From a theoretical framework, organoid biotechnology rapidly transformed into one of the most promising areas of biomedical research. Its evolution, as examined in this study, is a reflection of the remarkable interaction among biochemistry, genetics, and engineering — fields that together alter our understanding of development, illness, and regeneration [177]. From clarifying canonical pathways like Wnt and Notch to creating artificial biochemical circuits, organoid systems are increasingly used as predictive tools that can guide clinical judgments in addition to acting as

stand-ins for human physiology [178].

The quest for fidelity—ensuring organoids accurately express the biochemical, structural, and functional aspects of the tissues they represent—has emerged as a distinguishing theme. The precision required to improve disease modeling and lineage definition has been made possible by developments in CRISPR-driven genome editing and epigenetic reprogramming [179]. Concurrently, advancements in organoid-on-chip platforms and microfluidics have tackled the problem of controlling the biochemical microenvironment, making it possible to develop more physiologically appropriate and reproducible cultures [180]. These accomplishments highlight a paradigm shift from experimental mimicry to patient-tailored, predictive systems. Despite their effectiveness, these technologies continue to present a number of difficulties. Strong legal frameworks are still required because of biochemical heterogeneity, reproducibility issues, and ethical discussions, especially those involving brain organoids and their possible cognitive correlates [181]. The promising future of organoids runs the risk of being limited by unfairness and mistrust if ethics, openness, and accessibility are not given careful consideration. However, bringing organoid-based treatments to the clinic still requires industrial scale and regulatory harmonization.

Organoids have the potential to develop into highly personalized, sensitive, and predictive living representations of human biology. In the future, organoids will actively direct medical practice rather than just replicate tissue, as indicated by the convergence of AI, customized biobanking, and interdisciplinary collaboration [182]. The ability to model, forecast, and intervene in human health with previously unheard-of precision and care could be one of the most significant developments in contemporary medicine if this goal is ethically implemented.

11. References

1. Verstegen MMA, Coppes RP, Beghin A, *et al*. Clinical applications of human organoids. Nat Med. 2025;31:409-21.
2. Yao X, Smith J, Li Y, *et al*. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine. MedComm. 2024. [Epub ahead of print].
3. Edmondson R, Broglie JJ, Adcock AF, Yang L. Advances in development and application of human organoids. Cell Biosci. 2022;12:39.
4. Carnero A, Blanco-Aparicio C, Cascallana JL, *et al*. 3D and organoid culture in research: physiology, hereditary genetic diseases and cancer. Cell Biosci. 2022;12:39.
5. Zhu Z, Cheng Y, Liu X, *et al*. Advances in the development and application of human organoids: techniques, applications, and future perspectives. Cell Transplant. 2025. [Epub ahead of print].
6. Corrò C, Novellasdemunt L, Li VSW, *et al*. Primary human organoid models: current progress and key milestones. J Transl Med. 2020;18(1):275.
7. Lancaster MA, Knoblich JA. Modelling human brain development and disease with organoids. Nat Rev Mol Cell Biol. 2025;26(2):123-37.
8. Jensen LH, Rasmussen MH, Nielsen SL, *et al*. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing. J Exp Clin Cancer Res. 2023;43:61.
9. Letai A. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2021;39(4):450-6.
10. Driehuis E, Kolders S, Spelier S, *et al*. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov. 2020;9(7):852-71.
11. Annual Review of Biomedical Engineering. Human organoids as an emerging tool for genome screenings. Annu Rev. 2025;27:122327.
12. Nature Review. Breakthroughs and challenges of organoid models for assessing... Cell Death Discov. 2025;3:210.
13. Sato T, Vries RG, Snippert HJ, *et al*. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262-5.
14. Huch M, Koo BK. Modeling mouse and human development using organoid cultures. Development. 2015;142(18):3113-25.
15. Yin X, Mead BE, Safaee H, *et al*. Engineering stem cell organoids. Cell Stem Cell. 2016;18(1):25-38.
16. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18(3):246-54.
17. Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019;68(12):2228-37.
18. Corrò C, Novellasdemunt L, Li VSW. A brief history of organoids. Am J Physiol Cell Physiol. 2020;319(1):C151-C165.
19. Antoni D, Burckel H, Josset E, Noel G. Three-dimensional cell culture: A breakthrough in vivo. Int J Mol Sci. 2015;16(3):5517-27.
20. Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586-97.
21. Lancaster MA, Renner M, Martin CA, *et al*. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501(7467):373-9.
22. Quadrato G, Brown J, Arlotta P. The promises and challenges of human brain organoids as models of neuropsychiatric disease. Nat Med. 2016;22(11):1220-8.
23. Seok J, Warren HS, Cuenca AG, *et al*. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110(9):3507-12.
24. van der Worp HB, Howells DW, Sena ES, *et al*. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7(3):e1000245.
25. Kaushik G, Ponnusamy MP, Batra SK. Concise Review: Current status of three-dimensional organoids as preclinical models. Stem Cells. 2018;36(9):1329-40.
26. Rajasekar S, Lin DSY, Abdul R, *et al*. IFlowPlate: A customized 384-well plate for the culture of perfusable vascularized human organoids. Lab Chip. 2020;20(15):2693-706.
27. Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today. 2016;21(9):1399-411.
28. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169(6):985-99.
29. Koo BK, Spit M, Jordens I, *et al*. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665-9.
30. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch

signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770-6.
31. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13(7):513-32.
32. Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14(7):416-29.
33. Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163(4):811-28.
34. Takebe T, Wells JM, Wells C, *et al*. Organoid technologies for science and medicine. Cell Stem Cell. 2018;22(6):810-29.
35. Zeng H, Sanes JR. Neuronal cell-type classification: challenges, opportunities and the path forward. Nat Rev Neurosci. 2017;18(9):530-46.
36. Zhou Q, Melton DA. Pancreas regeneration. Nature. 2018;557(7705):351-8.
37. Li X, Nadauld L, Ootani A, *et al*. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med. 2014;20(7):769-77.
38. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, *et al*. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-30.
39. Atlasi Y, Stunnenberg HG. The interplay of epigenetic marks during stem cell differentiation and development. Nat Rev Genet. 2017;18(11):643-58.
40. Kim M, Costello J. DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med. 2017;49(4):e322.
41. Neri F, Rapelli S, Krepelova A, *et al*. Intragenic DNA methylation prevents spurious transcription initiation. Nature. 2017;543(7643):72-7.
42. Batista PJ, Molinie B. Epitranscriptomic regulation of stem cell fate decisions. Science. 2017;355(6329):1417-20.
43. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608-24.
44. Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303-22.
45. Liu J, Harada BT, He C. Regulation of gene expression by N6-methyladenosine in cancer. Trends Cell Biol. 2019;29(6):487-99.
46. Hu H, Yang Y, Ji Q, *et al*. Epitranscriptomic control of human organoid fate and function. Nat Cell Biol. 2021;23(9):905-16.
47. Weng H, Huang H, Wu H, *et al*. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 2018;22(2):191-205.e9.
48. Xue C, Chu Q, Shi Q, *et al*. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106.
49. Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407-18.
50. Schwank G, Koo BK, Sasselli V, *et al*. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13(6):653-8.
51. Bell CC, Hendriks DF, Moro SML, *et al*. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep. 2016;6:25187.
52. Michels BE, Mosa MH, Grebbin BM, *et al*. Human colon organoids reveal distinct phases of crypt formation and link Wnt and BMP signaling to stem cell niche dynamics. Cell Stem Cell. 2020;26(6):869-85.e4.
53. Mariani J, Coppola G, Zhang P, *et al*. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell. 2015;162(2):375-90.
54. Kim H, Park HJ, Choi H, *et al*. Modeling G2019S-LRRK2 mutation in Parkinson's disease using patient-derived brain organoids. NPJ Parkinsons Dis. 2019;5(1):5.
55. Río P, Navarro S, Wang W, *et al*. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned Fanconi anemia patients. Nat Med. 2019;25(9):1396-401.
56. Hubert CG, Rivera M, Spangler LC, *et al*. A three-dimensional organoid culture system derived from human glioblastomas reproduces the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res. 2016;76(8):2465-77.
57. Broutier L, Mastrogiovanni G, Verstegen MMA, *et al*. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424-35.
58. Ramalho-Santos M, Willenbring H. On the origin of the term "stem cell". Cell Stem Cell. 2007;1(1):35-8.
59. Repina NA, Rosenbloom A, Mukherjee A, *et al*. At-light-speed control of mammalian cells. Nat Chem Biol. 2019;15(6):549-55.
60. Muncie JM, Ayad NME, Lakins JN, *et al*. Mechanical tension promotes formation of gastrulation-like nodes and patterns mesoderm specification in human embryonic stem cells. Dev Cell. 2020;55(6):679-94.e11.
61. Artegiani B, Hendriks D, Beumer J, *et al*. Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. Nat Cell Biol. 2020;22(3):321-31.
62. Trujillo CA, Gao R, Negraes PD, *et al*. Complex oscillatory waves emerging from cortical organoids model early human brain network development. Cell Stem Cell. 2019;25(4):558-69.e7.
63. Piersma B, Bank RA, Boersema M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med. 2015;2:59.
64. Karzbrun E, Kshirsagar A, Cohen SR, *et al*. Human brain organoids on a chip reveal the physics of folding. Nat Phys. 2018;14(5):515-22.
65. Liu Y, Yu C, Daley TP, *et al*. CRISPR activation and interference screens in mammalian cells. Nat Protoc. 2018;13(2):307-28.
66. Yin H, Song CQ, Suresh S, *et al*. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35(12):1179-87.
67. Anzalone AV, Randolph PB, Davis JR, *et al*. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-57.
68. Kadosh E, Snir O. Epigenetic regulation in stem cell differentiation and organoid development. Stem Cells Int. 2021;2021:1-12.
69. Amiri A, Coppola G, Scuderi S, *et al*. Transcriptome and epigenome landscape of human cortical development

modeled in organoids. Science. 2018;362(6420):eaat6720.
70. Vlachogiannis G, Hedayat S, Vatsiou A, *et al*. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-6.
71. Li HB, Tong J, Zhu S, *et al*. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338-42.
72. Geula S, Moshitch-Moshkovitz S, Dominissini D, *et al*. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science. 2015;347(6225):1002-6.
73. Hnisz D, Schuijers J, Lin CY, *et al*. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Cell. 2015;159(2):362-76.
74. Nissim L, Perli SD, Fridkin A, *et al*. Synthetic circuits for engineering immune responses. Nat Biotechnol. 2017;35(5):447-55.
75. Xue C, Chu Q, Shi Q, *et al*. Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):106.
76. Krawczyk K, Leclerc S, Martin C, *et al*. Synthetic biology for precision medicine in oncology. Trends Biotechnol. 2021;39(9):922-37.
77. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.
78. Grebenyuk S, Ranga A. Engineering organoid vascularization. Front Bioeng Biotechnol. 2019;7:39.
79. Takebe T, Sekine K, Kimura M, *et al*. Massive and reproducible liver bud formation in vitro using human pluripotent stem cells. Nature. 2017;499(7459):481-5.
80. Chen Y, Li Y, Narayan R, *et al*. FGF and PDGF orchestrate vascular stability in engineered liver organoids. Nat Commun. 2020;11:3047.
81. Homan KA, Gupta N, Kroll KT, *et al*. Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods. 2019;16(3):255-62.
82. Wörsdörfer P, Dalda N, Kern A, *et al*. Generation of complex human organoid models including vascular networks by incorporation of mesodermal progenitor cells. Sci Rep. 2019;9:15663.
83. Ben-David U, Benvenisty N. Immune tolerance in stem-cell-derived transplants. Nat Rev Immunol. 2019;19(10):624-36.
84. Zhao T, Zhang ZN, Rong Z, *et al*. Immunogenicity of induced pluripotent stem cells. Nature. 2015;474(7350):212-5.
85. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunity. 2008;28(3):288-96.
86. Xu H, Wang B, Ono M, *et al*. Targeted disruption of HLA genes via CRISPR-Cas9 generates hypoimmunogenic human pluripotent stem cells. Nat Biotechnol. 2019;37(3):252-8.
87. Allan DSJ, Chakraborty M, McCluskey J, *et al*. Biochemical conditioning of organoids for reduced immunogenicity. Stem Cell Reports. 2020;15(4):936-50.
88. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010;21(12):1641-55.
89. Courau T, Bonnereau J, Chicoteau J, *et al*. Smart immunomodulatory organoids for transplantation. Nat Biomed Eng. 2019;3(7):566-77.
90. Hu H, Gehart H, Artegiani B, *et al*. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell. 2018;175(6):1591-606.
91. Takebe T, Zhang RR, Koike H, *et al*. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc. 2015;10(5):779-93.
92. Freedman BS, Brooks CR, Lam AQ, *et al*. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 2015;6:8715.
93. Garreta E, Prado P, Tarantino C, *et al*. Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells. Nat Mater. 2019;18(4):397-405.
94. Watson CL, Mahe MM, Múnera J, *et al*. An in vivo model of human small intestine using pluripotent stem cells. Nat Med. 2014;20(11):1310-4.
95. Sugimoto S, Ohta Y, Fujii M, *et al*. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell. 2018;22(2):171-6.e5.
96. van de Wetering M, Francies HE, Francis JM, *et al*. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933-45.
97. Dekkers JF, Whittle JR, Norton EJ, *et al*. High-throughput screening of organoid cultures. Nat Rev Drug Discov. 2020;19(5):275-92.
98. Sachs N, de Ligt J, Kopper O, *et al*. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1-2):373-86.e10.
99. Tiriac H, Belleau P, Engle DD, *et al*. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112-29.
100. Fiorini E, Veghini L, Coronnello M, *et al*. Automated imaging and machine learning analysis of organoid drug response. Nat Biomed Eng. 2020;4(9):862-74.
101. Park SE, Georgescu A, Huh D. Organoids-on-a-chip and their potential for personalized medicine. Lab Chip. 2019;19(7):1176-90.
102. Mills RJ, Parker BL, Quaife-Ryan GA, *et al*. Drug screening in human cardiac organoids reveals off-target cardiotoxicity. Nat Commun. 2019;10:5561.
103. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
104. Yan HHN, Siu HC, Law S, *et al*. A comprehensive human gastric cancer organoid biobank captures tumor subtype diversity. Nat Med. 2018;24(7):1132-45.
105. Berkers G, van Mourik P, Vonk AM, *et al*. Biobanking of patient-derived organoids to guide precision medicine in cystic fibrosis. Nat Med. 2019;25(5):712-9.
106. Ooft SN, Weeber F, Dijkstra KK, *et al*. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer. Sci Transl Med. 2019;11(513):eaay2574.
107. Kim J, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol. 2020;21(10):571-84.
108. Verissimo CS, Overmeer RM, Ponsioen B, *et al*. Integrating organoid drug screening with machine

learning for precision oncology. Nat Commun. 2020;11:5131.
109. Hollebecque A, Massard C, Postel-Vinay S, *et al*. Using organoids to predict and overcome drug resistance in cancer therapy. Nat Rev Clin Oncol. 2021;18(6):385-402.
110. Nanki K, Fujii M, Shimokawa M, *et al*. Somatic driver mutations in organoids provide insight into drug resistance. Nature. 2020;582(7812):506-11.
111. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309.
112. Ramirez M, Rajaram S, Steininger RJ, *et al*. Diverse drug-resistance mechanisms in cancer revealed by single-cell sequencing and organoid modeling. Nat Med. 2016;22(9):1056-63.
113. Sharma SV, Lee DY, Li B, *et al*. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69-80.
114. Hirata E, Girotti MR, Viros A, *et al*. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments. Nature. 2015;520(7547):358-62.
115. Kim HJ, Li H, Collins JJ, Ingber DE. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci U S A. 2016;113(1):E7-E15.
116. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760-72.
117. Rajan SAP, Skardal A, Hall AR. Liver-on-a-chip technologies for drug testing and disease modeling. Lab Chip. 2020;20(7):1112-32.
118. Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-on-a-chip engineering. Nat Rev Mater. 2018;3(8):257-78.
119. Maoz BM, Herland A, FitzGerald EA, *et al*. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat Biotechnol. 2018;36(9):865-74.
120. Huebsch N, Loskill P, Mandegar MA, *et al*. Automated video-based analysis of contractility and calcium flux in human iPSC-derived cardiomyocytes cultured over engineered heart tissue. Nat Methods. 2015;12(6):617-26.
121. Vernetti LA, Senutovitch N, Boltz R, *et al*. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med. 2017;242(16):1605-19.
122. Bredenoord AL, Clevers H, Knoblich JA. Human tissues in a dish: The research and ethical implications of organoid technology. Science. 2017;355(6322):eaaf9414.
123. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, *et al*. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38(4):e100300.
124. Luo C, Lancaster MA, Castanon R, *et al*. Cerebral organoids recapitulate epigenomic signatures of the human fetal neocortex. Nat Neurosci. 2016;19(1):56-63.
125. Camp JG, Badsha F, Florio M, *et al*. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci U S A. 2015;112(51):15672-7.
126. Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10(9):1886-90.
127. Gjorevski N, Sachs N, Manfrin A, *et al*. Designer matrices for intestinal stem cell and organoid culture. Nature. 2016;539(7630):560-4.
128. Brandenberg N, Hoehnel S, Kuttler F, *et al*. High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nat Biomed Eng. 2020;4(8):863-74.
129. Lei Y, Schaffer DV, Li W. A chemically defined culture system for human pluripotent stem cell expansion and differentiation. Nat Methods. 2019;16(6):561-9.
130. The Human Organoid Biobank Initiative. Global standards for reproducible organoid research. Nat Biotechnol. 2024;42(3):311-9.
131. Lavazza A, Massimini M. Cerebral organoids: ethical issues and consciousness assessment. J Med Ethics. 2018;44(9):606-10.
132. Farahany NA, Greely HT, Hyman S, *et al*. The ethics of experimenting with human brain tissue. Nature. 2018;556(7702):429-32.
133. Greely HT. Human brain organoids: science, ethics, and governance. Neuron. 2021;109(7):1069-72.
134. Koplin JJ, Savulescu J. Moral limits of brain organoid research. Bioethics. 2019;33(6):698-704.
135. Sawai T, Hatta T, Fujita M, *et al*. Minding the ethics of brain organoid research. Nat Methods. 2020;17(7):641-3.
136. Hyun I, Scharf-Deering JC, Lunshof JE. Ethical issues related to brain organoid research. Brain Res. 2020;1732:146-53.
137. Qian X, Song H, Ming GL. Brain organoids: advances, applications and challenges. Development. 2019;146(8):dev166074.
138. Brassard JA, Nikolaev M, Hübscher T, *et al*. Recapitulating macro-scale tissue self-organization through organoid bioprinting. Nat Mater. 2021;20(1):22-9.
139. Hofer M, Lutolf MP. Engineering organoids. Nat Rev Mater. 2021;6(5):402-20.
140. U.S. Food & Drug Administration. Draft guidance on organoid-based therapeutic products. FDA.gov. 2024.
141. Pampaloni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839-45.
142. Cohen IG, Adashi EY. Intellectual property and human organoids. Nat Biotechnol. 2023;41(5):542-4.
143. Chen Y, Kim J, Molinaro AM. Organoid systems biology: AI integration for precision control. Trends Biotechnol. 2022;40(12):1301-13.
144. Li X, Chou SJ, He Z. Machine learning approaches in organoid research. Nat Rev Bioeng. 2023;1(2):125-38.
145. Zeng H, Park JY, Kang J, *et al*. Multi-omics integration with AI for organoid development. Cell Stem Cell. 2023;30(4):552-66.
146. Sun Y, Wu H, Li T, *et al*. Reinforcement learning in organoid pathway optimization. Nat Comput Sci. 2024;4(4):305-16.
147. Sachs N, Clevers H. Organoids for precision oncology. Annu Rev Cancer Biol. 2020;4:113-34.
148. Rivron NC, Pera M, Rossant J. Automated imaging and analysis of organoid morphogenesis. Nat Protoc. 2021;16(5):2532-49.
149. Yang C, Zhao J, Xu W. Digital twins for organoid-based medicine. Front Bioeng Biotechnol. 2024;12:142567.